臺灣核心實作指引(TW Core IG)
0.3.2 - Ci-Build Trial Use
臺灣核心實作指引(TW Core IG)
0.3.2 - Ci-Build Trial Use
臺灣核心實作指引(TW Core IG), published by 衛生福利部. This guide is not an authorized publication; it is the continuous build for version 0.3.2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cctwFHIRterm/MOHW_TWCoreIG_Build/ and changes regularly. See the Directory of published versions
Generated Narrative: QuestionnaireResponse qr-example
| LinkID | Text | Definition | Answer |
|---|---|---|---|
  qr-example | Questionnaire:Medication or Other Substance | ||
  Medication/header | |||
  0 | Form ID: | 000 | |
| 74080-3/74081-1 | Event ID: | 456 | |
 74080-3/30947-6 | Initial Report Date (HERF Q1) | 2016-03-14 | |
| Medication/SEC00 | Medication or Other Substance | ||
 Medication/SEC01/74080-3 | |||
| 74080-3/74076-1 | What type of medication/substance was involved? | LOINC LA20271-5: Medications | |
| 74080-3/74075-3 | What type of medication? | LOINC LA20278-0: Prescription or over-the-counter (including herbal supplements) | |
| 74080-3/74072-0 | Which of the following best characterizes the event? | LOINC LA20275-6: Incorrect action (process failure or error) (e.g., such as administering overdose or incorrect medication) | |
| 74080-3/74071-2 | What was the incorrect action? | LOINC LA20276-4: Incorrect patient | |
| 74080-3/74063-9 | At what stage in the process did the event originate, regardless of the stage at which it was discovered? | LOINC LA20296-2: Administering | |
| 74080-3/74078-7 | |||
| 74080-3/74078-7/74062-1 | Generic name or investigational drug name | Acetaminophen | |
| 74080-3/74078-7/74055-5 | Dosage form of Product | Tablet | |
| 74080-3/74078-7/74053-0 | Was this medication/substance prescribed for this patient? | LOINC LA32-8: No | |
| Medication/74052-2 | Was this medication/substance given to this patient? | LOINC LA33-6: Yes | |
| Documentation for this format | |||